Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104500 · ClinicalTrials.gov registry record · Phase 3
VK2735 for Weight Management Phase 3
A Phase 3 study of Weight Loss, sponsored by Viking Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 4,500
- Enrollment target
- 20
- Study locations
NCT07104500: Active Phase 3 study of Weight Loss, sponsored by Viking Therapeutics.
NCT07104500 is a Phase 3 study of Weight Loss that is active but no longer recruiting, run by Viking Therapeutics. The registered enrollment target is 4,500 participants, above the 1,463-participant average among 116 other Weight Loss trials with a reported enrollment target (208% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104500, a Phase 3 study of Weight Loss, is active but no longer recruiting, sponsored by Viking Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Conditions Studied
Interventions
- DRUG VK2735
Study Locations (20)
California
- Viking Clinical Site #1071 - Chula Vista
- Viking Clinical Site #1070 - Escondido
- Viking Clinical Site #1054 - Huntington Park
- Viking Clinical Site #1014 - Lake Forest
- Viking Clinical Site #1129 - Lemon Grove
- Viking Clinical Site #1051 - Lincoln
- Viking Clinical Site #1050 - Long Beach
- Viking Clinical Site #1055 - Los Angeles
- Viking Clinical Site #1078 - Manteca
- Viking Clinical Site #1053 - Montclair
Arizona
- Viking Clinical Site #1005 - Chandler
- Viking Clinical Site #1017 - Flagstaff
- Viking Clinical Site #1018 - Peoria
- Viking Clinical Site #1135 - Scottsdale
- Viking Clinical Site #1019 - Tucson
Alabama
- Viking Clinical Site #1037 - Birmingham
- Viking Clinical Site #1064 - Birmingham
- Viking Clinical Site #1128 - Huntsville
- Viking Clinical Site #1081 - Mobile
Arkansas
- Viking Clinical Site #1036 - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 3 |
What the registry record for NCT07104500 still lists
NCT07104500 is an interventional study that assigns participants to a tested intervention. Its 4,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,463-participant average among 116 other Weight Loss trials with a reported enrollment target (208% higher).
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which VK2735 is the first listed.
NCT07104500 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07104500 about?
NCT07104500 is a clinical study titled "VK2735 for Weight Management Phase 3". This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27...
What is the current status of trial NCT07104500?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 4,500 participants. The study started on 2025-06-23. Estimated completion is 2027-08-01.
What conditions does trial NCT07104500 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT07104500?
The interventions under investigation include: VK2735 (DRUG).
Who is sponsoring clinical trial NCT07104500?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104500 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07104500's enrollment target sits among peer trials
4,500 4th of 116 higher than 113 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
RECRUITING · Phase 3
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- NCT07207564 · 4,500 participants
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI